You just read:

Capricor Therapeutics Announces the First Patient with Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated with CAP-1002 in the HOPE-Duchenne Phase I/II Clinical Trial

News provided by

Capricor Therapeutics, Inc.

Feb 22, 2016, 08:00 ET